Home › Trial NCT00184015
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
- Trial IDNCT00184015
- StatusUnknown
- PhasePhase 1/2
- Study typeInterventional
- SponsorUniversity of Southern California
- Enrollment50
- Start date2005-08-18
- ConditionsRenal Cell Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.